EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial

Ying Liu, Dairong Li, Lin Wu, Xingya Li, Yun Fan, Mingjun Zhang, Jun Guo, Yu Yao, Jian Fang, Ke-Jing Tang, Feng Luo, Yan Yu und 13 weitere

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.06.003 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Ying Liu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Jilin Cancer Hospital, Changchun, China. Electronic address: yingliu700930@foxmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Trastuzumab deruxtecan (T-DXd) was approved in China in October 2024 for previously treated human epidermal growth factor receptor 2 (HER2)-mutant (HER2m) unresectable/metastatic non-small cell lung cancer (NSCLC), based on DESTINY-Lung02 and DESTINY-Lung05 primary results. Here, we report the DESTINY-Lung05 final analysis. METHODS: DESTINY-Lung05 (NCT05246514), an open-label, single-arm, multicenter, phase 2 study, investigated T-DXd (5.4 mg/kg once every 3 weeks) in patients from China with HER2m (locally or centrally confirmed activating HER2 exon 19/20 mutation) metastatic NSCLC with disease progression on/after ≥ 1 prior anticancer therapy. The primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 by independent central review (ICR). Secondary endpoints included progression-free survival (PFS) by ICR, overall survival (OS), and safety. RESULTS: As of November 4, 2024, 72 patients with HER2m NSCLC had received T-DXd 5.4 mg/kg; the median duration of follow-up was 20.2 months (range, 2-27). Confirmed ORR (ICR) was 56.9% (95% confidence interval [CI] 44.7-68.6). Median PFS (ICR) and OS were 9.9 months (95% CI 7.1-16.5) and 21.0 months (95% CI 17.5-not calculable), respectively. Grade ≥ 3 drug-related adverse events occurred in 40 (55.6%) patients. Adjudicated drug-related interstitial lung disease/pneumonitis events were observed in 9 (12.5%) patients (n = 8 grade 1/2; n = 1 grade 3). CONCLUSIONS: With extended follow-up, T-DXd continued to demonstrate clinically meaningful and durable antitumor activity in patients from China with pretreated HER2m metastatic NSCLC, with no new safety signals. Results affirm the use of T-DXd as a treatment option in China for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedAgedChinaMutationMaleAdultCamptothecin

Stichwörter der Autor:innen

Antibody-drug conjugateHER2-altered NSCLCHER2-mutated NSCLCT-DXdTargetable mutations

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecanImmunoconjugatesAntibodies, Monoclonal, HumanizedCamptothecin

Autor:innen und Institutionen

  • Medical Oncology, Jilin Cancer Hospital, Changchun, China. Electronic address: yingliu700930@foxmail.com.
  • Department of Medical Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.
  • 2nd Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China Hunan Cancer Hospital, Changsha, China.
  • Oncology Department Second Ward, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Medical Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou, China.
  • Oncology Department, The Second Hospital of Anhui Medical University, Hefei, China.

Förderung

  • AstraZeneca

Zitieren

APA

Liu, Y., Li, D., Wu, L., Li, X., Fan, Y., Zhang, M., Guo, J., Yao, Y., Fang, J., Tang, K. J., Luo, F., Yu, Y., Min, X., Song, Z., Hu, J., Ma, R., Yang, H., Shu, Y., Xu, R., …, & Fang, Y. (2026). Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.06.003

Vancouver

Liu Y, Li D, Wu L, Li X, Fan Y, Zhang M, et al. Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.06.003

BibTeX
@article{Liu2026,
  author = {Liu, Ying and Li, Dairong and Wu, Lin and Li, Xingya and Fan, Yun and Zhang, Mingjun and Guo, Jun and Yao, Yu and Fang, Jian and Tang, Ke-Jing and Luo, Feng and Yu, Yan and Min, Xuhong and Song, Zizheng and Hu, Jie and Ma, Rui and Yang, Huaping and Shu, Yongqian and Xu, Ruilian and Wang, Buhai and Dong, Xiaorong and Chen, Yunru and Mao, Rui and Zhang, Victor and Fang, Yong},
  title = {Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.06.003}
}
Kostenlos starten →